Intriguingly, among the IDH2-mutated subgroup a CRc rate of 86%, a CR rate of 56% and a not reached median OS have been observed, demonstrating a unique benefit for these AML patients with VEN-AZA. The gene discussed is IDH2; the disease is acute myeloid leukemia.